TScan Therapeutics, Inc.
- TCRX
- NASDAQ
- Biotechnology
- TCR-T Cell Therapy
- Cancer Immunotherapy
$0.21
Today −9.00%Quote Oct 19, 2026, 08:00 PM UTC
−32.61%over the last month
Max drawdown −42.3%From 1-month high −42.3%3 months −77.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
138
Founded
2018
Market value
$27.3M
Approximate share count
Analyst target
$1.00
+375.7% from here
Floor
$0.21
2.4% below price
Resistance
$0.23
8.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TCRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free